1.Is Carotid Artery Ultrasound Still Useful Method for Evaluation of Atherosclerosis?.
Korean Circulation Journal 2017;47(1):1-8
Carotid ultrasound is an imaging modality that allows non-invasive assessment of vascular anatomy and function. Carotid intima-media thickness (IMT) has been shown to predict cardiovascular (CV) risk in multiple large studies. However, in 2013, American College of Cardiology/American Heart Association guidelines designated that the carotid IMT as class III evidence level was not recommended for use in clinical practice as a routine measurement of risk assessment for a first atherosclerotic CV event. Following the announcement of this guideline, combined common carotid IMT and plaque, including plaque tissue characterization and plaque burden, using 3D ultrasound was reported to be better than either measurement alone in a variety of studies. Moreover, changes in the intima thickness were related to aging and early atherosclerosis, and remodeling of the media thickness was associated with hypertension. Separate measurement is useful for evaluating the effects of different atherosclerotic risk factors on the arterial wall; however, a more detailed and elaborate technique needs to be developed. If so, separate measurement will play an important role in the assessment of atherosclerosis and arterial wall change according to a variety of risk factors, such as metabolic syndrome. In addition, although carotid blood flow velocity is a useful tool for risk classification and prediction in clinical practice, further clinical research is needed. The value of carotid IMT by ultrasound examination for risk stratification remains controversial, and groups developing future guidelines should consider the roles of plaque presence and burden and hemodynamic parameters in additional risk stratification beyond carotid IMT in clinical practice.
Aging
;
Atherosclerosis*
;
Blood Flow Velocity
;
Carotid Arteries*
;
Carotid Artery Diseases
;
Carotid Intima-Media Thickness
;
Carotid Stenosis
;
Classification
;
Heart
;
Hemodynamics
;
Hypertension
;
Methods*
;
Risk Assessment
;
Risk Factors
;
Ultrasonography*
2.A Message From the Editor-in-Chief.
Korean Circulation Journal 2012;42(10):651-651
No abstract available.
3.Role of Echocardiography in Small Animal Research.
Journal of the Korean Society of Echocardiography 1999;7(1):5-11
No abstract available.
Animal Experimentation*
;
Animals*
;
Echocardiography*
4.The Effect of Ablation for Paroxysmal Atrial Fibrillation on Left Atrial Volume and Function: A One-Year Follow-Up Study.
Jung Yeon CHIN ; Ho Joong YOUN
Yonsei Medical Journal 2014;55(4):895-903
PURPOSE: The effect of radiofrequency catheter ablation (RFCA) on left atrial (LA) volume and function in patients with paroxysmal atrial fibrillation (PAF) has not been extensively studied. The aim of this study was to evaluate the long-term impact of RFCA on LA volume and function in patients with PAF. MATERIALS AND METHODS: A total of 90 patients with drug-refractory PAF who had sinus rhythm on the initial echocardiogram were examined at baseline, 3 months and 1 year after ablation. We measured LA volume index, LA ejection fraction (LAEF; maximal-minimal LA volume/maximal LA volume), and LA active emptying fraction (LAAEF; mid-diastolic-minimal LA volume/mid-diastolic LA volume). RESULTS: After 12+/-1 months, 78 patients returned, and 61 patients (78%) had sinus rhythm. After 3 months, the LA maximal volume indices decreased (from 33+/-13 to 28+/-12 mL/m2; p<0.001). But, LAEF and LAAEF also decreased (from 48+/-13 to 39+/-12; p<0.001, from 27+/-13 to 19+/-11; p<0.001). After 1 year, LA volumes, LAEF, and LAAEF remained similar at 3 months. In patients without atrial fibrillation (AF) recurrence, LAEF and LAAEF decreased after 3 months (from 50+/-12 to 40+/-11; p<0.001, from 29+/-13 to 22+/-11; p<0.001) and did not change after 1 year. However, in patients with AF recurrence, those who did not have decreased levels after 3 months had significantly decreased after 1 year (from 43+/-14 to 34+/-11; p=0.026, from 22+/-12 to 15+/-10; p=0.012). CONCLUSION: Successful RFCA of PAF decreased LA volume and function at 3 months. At one year, LA volume and function was remained unchanged in successfully ablated patients whereas LA function in patients with AF recurrence worsened.
Adult
;
Aged
;
Atrial Fibrillation/*therapy
;
Atrial Function, Left/*physiology
;
*Catheter Ablation
;
Echocardiography
;
Female
;
Humans
;
Male
;
Middle Aged
;
Retrospective Studies
5.The Effect of Ablation for Paroxysmal Atrial Fibrillation on Left Atrial Volume and Function: A One-Year Follow-Up Study.
Jung Yeon CHIN ; Ho Joong YOUN
Yonsei Medical Journal 2014;55(4):895-903
PURPOSE: The effect of radiofrequency catheter ablation (RFCA) on left atrial (LA) volume and function in patients with paroxysmal atrial fibrillation (PAF) has not been extensively studied. The aim of this study was to evaluate the long-term impact of RFCA on LA volume and function in patients with PAF. MATERIALS AND METHODS: A total of 90 patients with drug-refractory PAF who had sinus rhythm on the initial echocardiogram were examined at baseline, 3 months and 1 year after ablation. We measured LA volume index, LA ejection fraction (LAEF; maximal-minimal LA volume/maximal LA volume), and LA active emptying fraction (LAAEF; mid-diastolic-minimal LA volume/mid-diastolic LA volume). RESULTS: After 12+/-1 months, 78 patients returned, and 61 patients (78%) had sinus rhythm. After 3 months, the LA maximal volume indices decreased (from 33+/-13 to 28+/-12 mL/m2; p<0.001). But, LAEF and LAAEF also decreased (from 48+/-13 to 39+/-12; p<0.001, from 27+/-13 to 19+/-11; p<0.001). After 1 year, LA volumes, LAEF, and LAAEF remained similar at 3 months. In patients without atrial fibrillation (AF) recurrence, LAEF and LAAEF decreased after 3 months (from 50+/-12 to 40+/-11; p<0.001, from 29+/-13 to 22+/-11; p<0.001) and did not change after 1 year. However, in patients with AF recurrence, those who did not have decreased levels after 3 months had significantly decreased after 1 year (from 43+/-14 to 34+/-11; p=0.026, from 22+/-12 to 15+/-10; p=0.012). CONCLUSION: Successful RFCA of PAF decreased LA volume and function at 3 months. At one year, LA volume and function was remained unchanged in successfully ablated patients whereas LA function in patients with AF recurrence worsened.
Adult
;
Aged
;
Atrial Fibrillation/*therapy
;
Atrial Function, Left/*physiology
;
*Catheter Ablation
;
Echocardiography
;
Female
;
Humans
;
Male
;
Middle Aged
;
Retrospective Studies
6.Treatment of Valvular Disease during Pregnancy.
Korean Circulation Journal 2003;33(12):1071-1080
No abstract available.
Pregnancy*
7.Unusual form of Cardiomyopathy.
Journal of the Korean Society of Echocardiography 2005;13(2):51-65
The cardiomyopathies constitute a group of diseases in which the dominant feature is direct involvement of the heart muscle itself. They are distinctive because they are not the result of pericardial, hypertensive, congenital, valvular, or ischemic diseases. Although the diagnosis of cardiomyopathy requires the exclusion of these etiological factors, the features of cardiomyopathy are often sufficiently distinctive-both clinically and hemodynamically-to allow a definitive diagnosis to be made. With increasing awareness of this condition, along with improvements in diagnostic techniques, cardiomyopathy is being recognized as a significant cause of morbidity and mortality. Whether the result of improved recognition or of other factors, the incidence and prevalence of cardiomyopathy appear to be increasing. A variety of schemes have been proposed for classifying the cardiomyopathies. The most widely recognized classification is that promulgated jointly by the World Health Organization (WHO) and the International Society and Federation of Cardiology (ISFC). In the WHO/ISFC classification, the cardiomyopathies are classified based on their predominant pathophysiological features; other diseases that affect the myocardium that are associated with a specific cardiac disorder or are part of a generalized systemic disorder are termed specific cardiomyopathies. Three basic types of functional impairment have been described: 1) dilated (DCM, formerly called congestive), the most common form, accounting for 60 percent of all cardiomyopathies and characterized by ventricular dilatation, contractile dysfunction, and often symptoms of congestive heart failure; 2) hypertrophic (HCM), recognized by inappropriate left ventricular hypertrophy, often with asymmetrical involvement of the interventricular septum, with preserved or enhanced contractile function until late in the course; and 3) restrictive (RCM), the least common form in western countries, marked by impaired diastolic filling and in some cases with endocardial scarring of the ventricle. Two other forms of cardiomyopathy are recognized: arrhythmogenic right ventricular cardiomyopathy and unclassified; the latter includes fibroelastosis, systolic dysfunction with minimal dilatation, and mitochondrial involvement. The distinction between the three major functional categories is not absolute, and often there is overlap; in particular, patients with HCM also have increased wall stiffness as a consequence of the myocardial hypertrophy and thus present some of the features of an RCM. Late in their course, ventricular dilation and systolic heart failure, bearing some resemblance to DCM, may occur. The aim of this review is to introduce the unusual forms of cardiomyopathy with the current literatures in this field.
Arrhythmogenic Right Ventricular Dysplasia
;
Cardiology
;
Cardiomyopathies*
;
Cicatrix
;
Classification
;
Diagnosis
;
Dilatation
;
Heart Failure
;
Heart Failure, Systolic
;
Humans
;
Hypertrophy
;
Hypertrophy, Left Ventricular
;
Incidence
;
Mortality
;
Myocardium
;
Prevalence
;
World Health Organization
8.Stroke and Echocardiography.
Journal of the Korean Society of Echocardiography 2005;13(4):135-151
Stroke, a sudden development of a focal neurologic deficit, remains as a frequent leading cause of death even in Korea. Five to 13% of strokes occur in patients with younger than 45 years of age; up to 40% of strokes occur in patients without occlusive cerebrovascular disease; and it is estimated that the source is cardiac origin in 15 to 20%. Another 30n to 40% are in the category of stroke of undetermined cause, also known as cryptogenic stroke. An increasing number of echocardiographic findings have been found in this group of cryptogenic stroke patients and in patients with embolic stroke. Cardiac tumors can be a source of emboli, but the most commonly implicated sources are thrombi from the left atrial appeadage or left ventricle, left atrial spontaneous contrast, atrial septal aneurysm associated with a patent foramen ovale (PFO), thrombi traversing a PFO, valve vegetations, protruding aortic atheroma of aortic arch, and emboli associated with mitral and aortic prostheses. Echocardiography is most helpful in defining the cause of cerebrovascular ischemia in patients without occlusive cerebrovascular disease. For complete evaluation of potential source of cardiac embolic sources, transesophageal echocardiography (TEE) is required because many of the entities such as left atrial appendage thrombus can be detected only with this technique.
Aneurysm
;
Aorta, Thoracic
;
Atrial Appendage
;
Cause of Death
;
Echocardiography*
;
Echocardiography, Transesophageal
;
Foramen Ovale, Patent
;
Heart Neoplasms
;
Heart Ventricles
;
Humans
;
Ischemia
;
Korea
;
Neurologic Manifestations
;
Plaque, Atherosclerotic
;
Prostheses and Implants
;
Stroke*
;
Thrombosis
9.Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Woo Baek CHUNG ; Ho Joong YOUN
The Korean Journal of Internal Medicine 2016;31(4):625-633
Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline.
Anthracyclines
;
Appointments and Schedules
;
Breast Neoplasms
;
Cardiotoxicity*
;
Comorbidity
;
Doxorubicin
;
Drug Therapy
;
Humans
;
Leukemia
;
Lymphoma
;
Myocardium
;
Sarcoma
10.Demonstration of Pathologic Coronary Flow Dynamics using Transthoracic Doppler Echocardiography: Its Potential Role in Clinical Decision-Making.
Korean Circulation Journal 2005;35(4):269-281
With advancements in high frequency transducers, transesophageal (TEE) and transthoracic Doppler echocardiography (TTE) are emerging as promising methods for the evaluation of coronary arteries. In addition to visualizing images for the detection of stenosis of the proximal and distal coronary arteries, as well as various kinds of coronary artery anomalies, the functional assessment through measurement of the coronary flow reserve using TEE and TTE have become valuable and additive tools for coronary angiography that define only the epicardial coronary arteries. Further efforts to develop new techniques, including real time 3D echocardiography, in the anatomic and functional assessments of coronary artery disease should be undertaken.
Constriction, Pathologic
;
Coronary Angiography
;
Coronary Artery Disease
;
Coronary Circulation
;
Coronary Vessels
;
Echocardiography
;
Echocardiography, Doppler*
;
Echocardiography, Three-Dimensional
;
Transducers